ICYMI: Caplacizumab benefits patients with acquired TTP

Patients with acquired thrombotic thrombocytopenic purpura (TTP) who were treated with caplacizumab had faster time to platelet normalization (2.69 days vs. 2.88 days) and were 1.55 times more likely to achieve platelet normalization, compared with placebo, according to results of the double-blind, controlled HERCULES trial published in the New England Journal of Medicine (2019 Jan 9. doi: 10.1056/NEJMoa1806311).

Patients taking caplacizumab also had a 74% lower incidence of a composite outcome that included TTP-related deaths, recurrence of TTP, or a major thromboembolic event.

We covered this story at the annual meeting of the American Society of Hematology before it was published in the journal. Find our coverage at the link below.

lfranki@mdedge.com

Patients with acquired thrombotic thrombocytopenic purpura (TTP) who were treated with caplacizumab had faster time to platelet normalization (2.69 days vs. 2.88 days) and were 1.55 times more likely to achieve platelet normalization, compared with placebo, according to results of the double-blind, controlled HERCULES trial published in the New England Journal of Medicine (2019 Jan 9. doi: 10.1056/NEJMoa1806311).

Patients taking caplacizumab also had a 74% lower incidence of a composite outcome that included TTP-related deaths, recurrence of TTP, or a major thromboembolic event.

We covered this story at the annual meeting of the American Society of Hematology before it was published in the journal. Find our coverage at the link below.

lfranki@mdedge.com

Patients with acquired thrombotic thrombocytopenic purpura (TTP) who were treated with caplacizumab had faster time to platelet normalization (2.69 days vs. 2.88 days) and were 1.55 times more likely to achieve platelet normalization, compared with placebo, according to results of the double-blind, controlled HERCULES trial published in the New England Journal of Medicine (2019 Jan 9. doi: 10.1056/NEJMoa1806311).

Patients taking caplacizumab also had a 74% lower incidence of a composite outcome that included TTP-related deaths, recurrence of TTP, or a major thromboembolic event.

We covered this story at the annual meeting of the American Society of Hematology before it was published in the journal. Find our coverage at the link below.

lfranki@mdedge.com